TransMedics drops as Q3 revenue misses analyst estimates

TransMedics

30/10/2025 10:49

** Shares of medtech company TransMedics TMDX.O fall 7% to $123.98 premarket after Q3 revenue miss

** Co posts Q3 rev of $143.8 mln

** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln

** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts

** TMDX raises 2025 revenue guidance to $595 mln-$605 mln

** Co announces collaboration with Mercedes-Benz for organ transport in Italy

** 10 out of 13 analysts rate stock "buy" or higher, three "hold"; the median PT at $147.50 - data compiled by LSEG

** TMDX stock UP 115.43% YTD, as of last close

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))